TABLE 1.

Characteristics of patients (n = 9) with ITP who achieved a durable PLT count response associated with the use of TRAs

Patient	Age (years)	Sex	ITP duration (years)	Number of prior treatments	Pretreatment PLT count (×109/L)	TRA	Treatment duration (months)*	Remission off TRA (months)	Relapse	Sustained remission†
1	59	Female	8	5	19	Romiplostim	5	20	No	Definite
2	37	Male	2	3	5	Romiplostim	0.5	28	No	Definite
3	80	Male	4	3	3	Romiplostim	11	11	No	Definite
4	21	Female	2	6	7	Eltrombopag	13	26	No	Possible
5	53	Male	16	4	23	Romiplostim	14.5	3	Yes	Possible
6	57	Male	11	6	6	Romiplostim	1	31	No	Possible
7	43	Female	17	3	11	Eltrombopag	11	3.5	Yes	Possible
8	30	Male	25	9	4	Romiplostim	0.5	8	Yes	Possible
9	21	Male	3	4	13	Eltrombopag	5	3	Yes	Possible

^*Treatment duration refers to first treatment course for those patients who relapsed.

^†Definite TRA-induced remission was defined as the achievement of a PLT count above 100 × 10⁹/L after TRA treatment that was maintained during treatment and that persisted even after treatment was discontinued, without the use of concomitant maintenance therapies, rituximab or splenectomy within 2 months before starting the TRA. A possible TRA-induced remission was defined as the achievement of a PLT count above 100 × 10⁹/L that persisted even after the TRA was discontinued, but either a relapse occurred or other disease-modifying treatments had been administered before the TRA.